KRTX - Karuna Therapeutics GAAP EPS of -$1.95 beats by $0.19

Karuna Therapeutics press release (NASDAQ:KRTX): Q1 GAAP EPS of -$1.95 beats by $0.19. Topline data from the Phase 3 EMERGENT-2 and EMERGENT-3 trials expected in the third quarter of 2022 and in the first quarter of 2023. The company is on track to initiate Phase 3 program evaluating KarXT for the treatment of psychosis in Alzheimer’s disease in mid-2022. The company has $443.2M in cash, which is expected to fund operations for at least 12 months following the potential New Drug Application (NDA) submission of KarXT for schizophrenia.

For further details see:

Karuna Therapeutics GAAP EPS of -$1.95 beats by $0.19